9 completed, 4 active not recruiting, 4 terminated, 2 recruiting. 24 Phase 2, 3 Phase 3, 1 Phase 1.
Follow Lupus Erythematosus, Discoid: new trials by email Literature Review of Lupus Erythematosus, Discoid trials Research Report on Lupus Erythematosus, Discoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus Afimetoran, Placebo - Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus | Phase 2 / Phase 3 | Recruiting | Beeline Medicines Corporation | 390 | 2026-10-01 | 2026-10-29 |
| A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus Dihydroartemisinin tablets, Hydroxychloroquine tablets - Discoid Lupus Erythematosus | Phase 2 | Not yet recruiting | Kunming Pharmaceuticals, Inc. | 100 | 2026-04-30 | 2026-04-30 |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) IMVT-1402, Placebo - Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 2 | Active not recruiting | Immunovant Sciences GmbH | 56 | 2025-02-19 | 2026-08-28 |
| Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus Ruxolitinib 1.5% cream, Application without occlusion in Area 1, Application under occlusion at night in Area 2 - Discoid Lupus Erythematosus | Phase 2 | Recruiting | Innovaderm Research Inc. | 20 | 2024-04-19 | 2025-03-24 |
| Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus Placebo, Daxdilimab - Discoid Lupus Erythematosus | Phase 2 | Terminated | Amgen | 72 | 2022-12-29 | 2026-05-14 |
| The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) M5049 low dose, M5049 medium dose, M5049 high dose - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 381 | 2022-09-16 | 2026-10-15 |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Litifilimab, Placebo - Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 2 / Phase 3 | Active not recruiting | Biogen | 450 | 2022-09-13 | 2026-10-23 |
| Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus Ruxolitinib - Discoid Lupus Erythematosus | Phase 2 | Completed | University of Rochester | 10 | 2022-05-04 | 2025-05-20 |
| The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose - Systemic Lupus Erythematosus | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 456 | 2022-03-31 | 2025-12-01 |
| A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Deucravacitinib, Placebo - Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 74 | 2021-07-12 | 2025-09-10 |
| A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus Secukinumab - Discoid Lupus Erythematosus | Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-09-01 | 2021-09-08 | |
| Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus. Delgocitinib cream, Delgocitinib cream vehicle - Discoid Lupus Erythematosus | Phase 2 | Terminated | LEO Pharma | 27 | 2019-07-09 | 2025-03-06 |
| Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Pulsed-dye Laser, Sham - Lupus Erythematosus, Discoid | Phase 2 / Phase 3 | Unknown | Chulalongkorn University | 24 | 2016-12-15 | 2017-06-06 |
| Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Etanercept - Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous | Phase 2 | Completed | University of Leeds | 25 | 2016-02-01 | 2019-02-27 |
| Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions R932333, Placebo - Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic | Phase 2 | Completed | Rigel Pharmaceuticals | 54 | 2012-08-01 | 2016-07-14 |
| A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus CC-930, Placebo - Discoid Lupus | Phase 2 | Terminated | Celgene | 5 | 2011-11-01 | 2019-11-19 |
| Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Alitretinoin - Lupus Erythematosus, Cutaneous | Phase 2 | Terminated | University Hospital Muenster | 7 | 2011-08-01 | 2016-06-01 |
| To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus CC-11050, Placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Amgen | 48 | 2010-10-01 | 2020-06-23 |
| The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus etanercept(Enbrel®) - Discoid Lupus Erythematosus (DLE) | Phase 2 | Unknown | Florida Academic Dermatology Centers | 20 | 2008-10-01 | 2010-05-26 |
| Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients CC-10004 - Discoid Lupus Erythematosus | Phase 1 / Phase 2 | Completed | NYU Langone Health | 8 | 2008-06-01 | 2021-03-03 |
Showing 20 of 24. Sign in to see all of them.
Lupus Erythematosus, Cutaneous (10) · Lupus Erythematosus, Systemic (4) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Skin Diseases (1)
Skin and Connective Tissue Diseases (24) · Connective Tissue Diseases (23) · Skin Diseases (23) · Lupus Erythematosus, Cutaneous (14) · Autoimmune Diseases (4) · Immune System Diseases (4)
Etanercept (2) · ruxolitinib (2) · 4-(9-(tetrahydrofuran-3-yl))-8-(2,4,6-trifluorophenylamino)-9H-purin-2-ylaminocyclohexan-1-ol (1) · Alitretinoin (1) · CC-11050 (1) · Hydroxychloroquine (1) · Lasers, Dye (1) · R333 (1) · Salicylic Acid (1) · Thalidomide (1) · apremilast (1) · artenimol (1) · deucravacitinib (1) · efalizumab (1) · secukinumab (1)
Amgen (2) · Astion Pharma A/S (2) · Beeline Medicines Corporation (1) · Biogen (1) · Bristol-Myers Squibb (1) · Celgene (1) · Chulalongkorn University (1) · EMD Serono Research & Development Institute, Inc. (1) · Florida Academic Dermatology Centers (1) · Immunovant Sciences GmbH (1) · Innovaderm Research Inc. (1) · Kunming Pharmaceuticals, Inc. (1) · LEO Pharma (1) · Massachusetts General Hospital (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)
United States (17) · Argentina (6) · Germany (6) · Poland (6) · Bulgaria (5) · Canada (5) · Brazil (4) · Chile (4) · China (4) · France (4) · Greece (4) · Mexico (4) · Serbia (4) · Spain (4) · Taiwan (4)
Andrew G Franks, Jr., MD (1) · Annegret Kuhn, Prof. Dr. (1) · Christopher T Richardson, MD, PhD (1) · Daniel Magilavy, MD (1) · Gideon Smith, MD (1) · Paul Emery, MD FMedSci (1) · Robert Bissonnette, MD (1) · William Smith, MD (1) · Wilma F Bergfeld, MD (1)
PMID 33687069, PMID 42107374, PMID 42107375
2015 (1), 2018 (1), 2023 (1)